Experimental CAR T-Cell therapy targets four rare blood cancers
NCT ID NCT05537766
First seen Mar 20, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This phase 2 trial tested a CAR T-cell therapy called brexucabtagene autoleucel in 19 adults with rare B-cell cancers that had come back or stopped responding to treatment. The cancers included Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia. The study aimed to see how many patients achieved a complete or partial response, but it was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY WALDENSTROM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162, Italy
-
Azienda Ospedale di Perugia - Ospedale S. Maria della Misericordia
Perugia, 06132, Italy
-
Centre hospitalier de Toulouse - Hematology department
Toulouse, 31059, France
-
City of Hope (City of Hope National Medical Center)
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Georgetown University Medical Centre
Washington D.C., District of Columbia, 20037, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hopital de la Pitie Salpetriere
Paris, 75013, France
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, 40138, Italy
-
Istituto Oncologico Della Svizzera Italiana (IOSI)
Bellinzona, 6500, Switzerland
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of Vienna, Department of Internal Medicine I, Div. of Hematology
Vienna, 01090, Austria
-
Radboud University Nijmegen Medical Centre
Nijmegen, 6525 GA, Netherlands
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
The Ohio State University Wexner Medical Center - James Cancer HospitalS
Columbus, Ohio, 43210, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Universitatsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitatsklinikum Koln
Cologne, 50937, Germany
-
Universitatsklinikum Ulm
Ulm, 89081, Germany
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brexucabtagene autoleucel (a CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If successful, this could provide a new treatment option for people with rare B-cell cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase study with only 19 participants, so results may not apply broadly. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.